Key result
Heparins and VKAs remain preferred over DOACs in non-bacterial thrombotic endocarditis.
Why the study?
New associations including SARS-CoV-2 infection, larger clinical series, updated guidance, and widespread TAVR use have changed the clinical context of non-bacterial thrombotic endocarditis (NBTE) since 2007, warranting an updated review of its management and relationship to bioprosthetic leaflet thrombosis after TAVR.
Answers are grounded in this paper and cite their sources.
This narrative review highlights that NBTE management relies on individualized anticoagulation (favoring heparins or VKAs in APS over DOACs) and TEE diagnosis while clarifying that post-TAVR subclinical leaflet thickening (HALT) is distinct from NBTE.
Background and Objective: Non-bacterial thrombotic endocarditis (NBTE) is characterised by sterile fibrin-platelet vegetations on cardiac valves and is associated principally with malignancy, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Since our 2007 review, new associations [including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection], larger clinical series, updated guidance and the widespread use of transcatheter aortic valve replacement (TAVR) have changed the clinical context. This narrative review updates the epidemiology, pathogenesis, diagnosis and management of NBTE and examines, without assuming equivalence, how NBTE relates to bioprosthetic leaflet thrombosis after TAVR.Methods: PubMed/MEDLINE, Embase, the Cochrane Library and Web of Science were searched from inception to 25 September 2026 for English-language publications on NBTE, Libman-Sacks endocarditis and bioprosthetic leaflet thrombosis, supplemented by hand-searching of reference lists, current guidelines and trial registries. Evidence was synthesised narratively.Key Content and Findings: The evidence base consists predominantly of retrospective cohorts, case series and case reports; no NBTE-specific randomised trial exists. Malignancy (particularly adenocarcinoma of the lung and pancreas), SLE and APS remain the dominant associations, and NBTE may be the first manifestation of an occult cancer. Transoesophageal echocardiography (TEE) is the principal diagnostic modality; cerebral magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) are adjuncts. No single clinical, imaging or laboratory feature excludes infective endocarditis, which requires a contemporary blood-culture-negative endocarditis work-up. Heparins are generally favoured on observational and indirect evidence, vitamin K antagonists (VKAs) are preferred in thrombotic APS, and direct oral anticoagulants (DOACs) should be used with caution. Subclinical hypo-attenuated leaflet thickening (HALT) after TAVR or surgical bioprosthetic replacement is a form of bioprosthetic valve thrombosis that is distinct from NBTE; any mechanistic overlap is hypothetical. Routine CT screening and routine anticoagulation after TAVR are not recommended.Conclusions: Management of NBTE remains individualised and multidisciplinary, guided by the underlying disease, bleeding risk and any independent indication for anticoagulation. Prospective registries with standardised definitions are needed to inform clinical practice, future trials and guideline development.
No takes yet. Share an insight, caveat, or question.
Asopa et al. (2026) conducted a review in Non-bacterial thrombotic endocarditis (NBTE) and bioprosthetic leaflet thrombosis after TAVR. Anticoagulation (heparins, vitamin K antagonists, direct oral anticoagulants) and diagnostic imaging (TEE, cerebral MRI, 18F-FDG PET/CT) was evaluated. Heparins and VKAs are favoured over DOACs in non-bacterial thrombotic endocarditis based on observational evidence, as 0 NBTE-specific randomised trials exist.
Synapse has enriched 10 related papers. Consider them for comparative context: